<?xml version='1.0' encoding='utf-8'?>
<document id="22735685"><sentence text="Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention."><entity charOffset="0-10" id="DDI-PubMed.22735685.s1.e0" text="Amlodipine" /><entity charOffset="12-23" id="DDI-PubMed.22735685.s1.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.22735685.s1.e0" e2="DDI-PubMed.22735685.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22735685.s1.e0" e2="DDI-PubMed.22735685.s1.e1" /></sentence><sentence text="To test the effect of a loss-of-function variation of the cytochrome P450 (CYP) 3A5 on drug-drug interaction between amlodipine and clopidogrel"><entity charOffset="117-127" id="DDI-PubMed.22735685.s2.e0" text="amlodipine" /><entity charOffset="132-143" id="DDI-PubMed.22735685.s2.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.22735685.s2.e0" e2="DDI-PubMed.22735685.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22735685.s2.e0" e2="DDI-PubMed.22735685.s2.e1" /></sentence><sentence text=" Amlodipine is a well-known inhibitor of CYP 3A4, an isoenzyme of CYP3A that activates clopidogrel"><entity charOffset="1-11" id="DDI-PubMed.22735685.s3.e0" text="Amlodipine" /><entity charOffset="87-98" id="DDI-PubMed.22735685.s3.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.22735685.s3.e0" e2="DDI-PubMed.22735685.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22735685.s3.e0" e2="DDI-PubMed.22735685.s3.e1" /></sentence><sentence text=" However, controversy exists regarding whether amlodipine adversely affects clopidogrel response and clinical outcome after percutaneous coronary intervention (PCI)"><entity charOffset="47-57" id="DDI-PubMed.22735685.s4.e0" text="amlodipine" /><entity charOffset="76-87" id="DDI-PubMed.22735685.s4.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.22735685.s4.e0" e2="DDI-PubMed.22735685.s4.e0" /><pair ddi="true" e1="DDI-PubMed.22735685.s4.e0" e2="DDI-PubMed.22735685.s4.e1" /></sentence><sentence text=" In the presence of CYP3A4 inhibitors such as amlodipine, the genetic variation of CYP3A5, the isoenzyme responsible for the backup CYP3A activity, may play an important role in clopidogrel activation"><entity charOffset="46-56" id="DDI-PubMed.22735685.s5.e0" text="amlodipine" /><entity charOffset="178-189" id="DDI-PubMed.22735685.s5.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.22735685.s5.e0" e2="DDI-PubMed.22735685.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22735685.s5.e0" e2="DDI-PubMed.22735685.s5.e1" /></sentence><sentence text="" /><sentence text="Post hoc analysis of a prospectively enrolled cohort" /><sentence text="" /><sentence text="Patients enrolled in the CROSS-VERIFY cohort from June 2006 to June 2010, with successful genotyping of CYP3A5" /><sentence text="" /><sentence text="The pharmacodynamic analysis end point was clopidogrel on-treatment platelet reactivity (OPR) and the clinical analysis end point was the composite of cardiac death, non-fatal myocardial infarction, ischaemic stroke and stent thrombosis at 12 months post-PCI"><entity charOffset="43-54" id="DDI-PubMed.22735685.s11.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="1258 patients had successful genotyping and were categorised as CYP3A5 non-expressers (749 patients) and expressers (509 patients) according to the CYP3A5 genotype" /><sentence text=" Amlodipine users showed higher OPR versus non-users only in CYP3A5 non-expressers (249 ± 83 vs 228 ± 84 P2Y12 reaction units, p=0"><entity charOffset="1-11" id="DDI-PubMed.22735685.s14.e0" text="Amlodipine" /></sentence><sentence text="013)" /><sentence text=" These findings was corroborated by clinical outcomes, in which amlodipine users had a higher incidence of events compared with non-users only in CYP3A5 non-expressers (4"><entity charOffset="64-74" id="DDI-PubMed.22735685.s16.e0" text="amlodipine" /></sentence><sentence text="6% vs 0" /><sentence text="6%, HR 7" /><sentence text="731, CI 2" /><sentence text="042 to 29" /><sentence text="264, p=0" /><sentence text="004)" /><sentence text="" /><sentence text="Treatment with amlodipine is associated with increased clopidogrel OPR and increased risk of thrombotic events after PCI, which is dependent on the CYP3A5 genetic status"><entity charOffset="15-25" id="DDI-PubMed.22735685.s24.e0" text="amlodipine" /><entity charOffset="55-70" id="DDI-PubMed.22735685.s24.e1" text="clopidogrel OPR" /><pair ddi="false" e1="DDI-PubMed.22735685.s24.e0" e2="DDI-PubMed.22735685.s24.e0" /><pair ddi="false" e1="DDI-PubMed.22735685.s24.e0" e2="DDI-PubMed.22735685.s24.e1" /></sentence><sentence text="" /></document>